ZymoGenetics, Cameco and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
As several of the major pharmaceutical companies struggle through a period of a relative dearth of big, new products, the job casualties and the share buybacks are piling up this earnings season. Today, Sanofi-Aventis is joining the group. The French drugmaker announced it will buy back more than $4 billion of its stock and get rid of even more sales reps.
Johnson & Johnson said Tuesday it planned to eliminate 3 percent to 4 percent of its global work force of about 120,500 people as part of a plan to improve its cost structure. The cost-cutting plan is expected to generate pretax cost savings of $1.3 billion to $1.6 billion in 2008, the diversified health care company said.
With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.
Investors picked up where they left off a week ago, as stock prices hurtled to new highs with the Dow Industrials setting another milestone, but a Friday selloff kind of spoiled the mood.
Caterpillar, Johnson & Johnson, Toyota and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The Dow Jones Industrial Average closed at a record high, but slipped below 14,000 after trading above the milestone earlier in the session. Traders remained optimistic that the market will power higher. "We're not going to stop at 14,000; it's just an arbitrary number," said Gordon Charlop, president of Walter J. Dowd.
Johnson & Johnson Tuesday said second-quarter profit rose on higher sales of medical devices and prescription drugs, beating Wall Street expectations on especially strong demand in overseas markets.
The headline might say, "Johnson & Johnson Beats the Street," but investors are looking behind it and that's what is pushing this Dow component down this morning. For example, JNJ says its topline growth would have been just 3.6% instead of 13% if it had not bought Pfizer's consumer health care business last year for $16.6 billion. JNJ is kind of a three-pronged hybrid: pharma, medical devices and consumer healthcare.
The CNBC Executive Leadership Awards honor executives who have shown exemplary leadership, inspiration and innovation. More than 300 business leaders attended the third annual gala at the Pierre Hotel in New York Wednesday night and paid special tribute to legendary Federal Reserve Board Chairman Alan Greenspan.
Earnings news is helping set the tone as some big positive reports are countering weakness in stocks ahead of inflation data.
Corporate America is on a share buyback binge, fueling concerns that U.S. companies are masking underlying business problems and trying to pump up their executives' compensation.
Johnson & Johnson said on Monday its board of directors approved the repurchase of up to $10 billion of its common stock.
Even with the July 4th holiday next week, analysts think the markets will be as jittery as ever. "The market is very nervous here," Steven Neimeth, portfolio manager at AIG SunAmerica Asset Management told CNBC.com. "Lower liquidity around the Fourth of July week could lead to greater volatility as a result of news events, whether it be the Middle East, oil or the credit markets. Any news, good or bad, is likely to have a heavy impact on the market."
On the surface, long-term "sensible" investor Warren Buffett and "Mad Money" trader Jim Cramer appear to have two very different styles and you wouldn't expect much agreement between them. But Stockpickr (a subsidiary of TheStreet.com) president James Altucher did some analysis of Cramer's take on Buffett's stocks and found a lot of common ground.
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift your money from one to the other. Luckily, Cramer knows the precise moment.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
On Wall Street, the Berkshire Hathaway chief is a god. But does he still have his mojo after all these years?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.